Chemed Reports Second-Quarter 2019 Results
Consolidated operating results:
- Revenue increased 7.2% to
$474 million - GAAP Diluted Earnings-per-Share (EPS) of
$3.08 - Adjusted Diluted EPS of
$3.36 , an increase of 19.6%
VITAS segment operating results:
- Net Patient Revenue of
$313 million , an increase of 5.4% - Average Daily Census (ADC) of 18,681, an increase of 5.9%
- Admissions of 17,491, an increase of 3.8%
- Net Income, excluding certain discrete items, of
$38.6 million , an increase of 21.5% - Adjusted EBITDA, excluding cap, of
$54.8 million , an increase of 25.6%
- Revenue of
$161 million , an increase of 10.9% - Net Income, excluding certain discrete items, of
$27.5 million , an increase of 8.7% - Adjusted EBITDA of
$38.8 million , an increase of 6.2% - Adjusted EBITDA margin of 24.1%, a decrease of 107-basis points
VITAS
VITAS net revenue was
In the second quarter of 2019, VITAS accrued
Of VITAS’ 30 Medicare provider numbers, on a trailing 12-month basis, 23 provider numbers have a Medicare Cap cushion of 10% or greater, two provider numbers have a cap cushion between 5% and 10%, two provider numbers have a cap cushion between 0% and 5%, and three provider numbers have a Medicare Cap billing limitation.
Average revenue per patient per day in the quarter was
The second quarter of 2019 gross margin, excluding Medicare Cap, was 23.7%, which is a 208-basis point increase when compared to the second quarter of 2018.
Selling, general and administrative expense was
Commercial drain cleaning revenue increased 9.9%, commercial plumbing and excavation increased 11.9% and commercial water restoration increased 16.2%. Overall, commercial revenue increased 11.0%.
Residential drain cleaning increased 7.7%, plumbing and excavation increased 9.6% and residential water restoration increased 13.8%. Aggregate residential sales increased 9.9%.
Roto-Rooter’s gross margin in the quarter was 48.7%, a 121-basis point decline when compared to the second quarter of 2018. Adjusted EBITDA in the second quarter of 2019 totaled
Chemed Consolidated
As of
In
During the quarter, the Company repurchased 69,009 shares of Chemed stock for
Chemed restarted its share repurchase program in 2007. Since that time Chemed has repurchased over 14 million shares, aggregating approximately
Updated Guidance for 2019
Chemed will issue updated guidance in
Conference Call
Chemed will host a conference call and webcast at
A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (855) 859-2056 for
Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name
This press release contains information about Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.
Forward-Looking Statements
Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements.
These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed’s dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed’s most recent report on form 10-Q or 10-K and its other filings with the
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||||||
CONSOLIDATED STATEMENT OF INCOME | ||||||||||||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||||||||||||
Three Months Ended |
|
Six Months Ended |
||||||||||||||||||||||||||
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||||||||||||||||
Service revenues and sales |
$ |
|
473,584 |
|
$ |
|
441,813 |
|
$ |
|
935,618 |
|
$ |
|
880,989 |
|
||||||||||||
Cost of services provided and goods sold |
323,637 |
|
305,741 |
|
645,588 |
|
610,277 |
|
||||||||||||||||||||
Selling, general and administrative expenses (aa) |
71,556 |
|
68,297 |
|
145,585 |
|
137,297 |
|
||||||||||||||||||||
Depreciation |
9,887 |
|
9,718 |
|
19,597 |
|
18,985 |
|
||||||||||||||||||||
Amortization |
406 |
|
34 |
|
925 |
|
61 |
|
||||||||||||||||||||
Other operating (income)/expenses |
2,570 |
|
(118 |
) |
8,923 |
|
(169 |
) |
||||||||||||||||||||
Total costs and expenses |
408,056 |
|
383,672 |
|
820,618 |
|
766,451 |
|
||||||||||||||||||||
Income from operations |
65,528 |
|
58,141 |
|
115,000 |
|
114,538 |
|
||||||||||||||||||||
Interest expense |
(1,237 |
) |
(1,524 |
) |
(2,361 |
) |
(2,731 |
) |
||||||||||||||||||||
Other income--net (bb) |
13 |
|
1,038 |
|
2,452 |
|
2,056 |
|
||||||||||||||||||||
Income before income taxes |
64,304 |
|
57,655 |
|
115,091 |
|
113,863 |
|
||||||||||||||||||||
Income taxes |
(13,575 |
) |
(2,684 |
) |
(19,695 |
) |
(13,896 |
) |
||||||||||||||||||||
Net income |
$ |
|
50,729 |
|
$ |
|
54,971 |
|
$ |
|
95,396 |
|
$ |
|
99,967 |
|
||||||||||||
Earnings Per Share | ||||||||||||||||||||||||||||
Net income |
$ |
|
3.18 |
|
$ |
|
3.43 |
|
$ |
|
5.98 |
|
$ |
|
6.22 |
|
||||||||||||
Average number of shares outstanding |
15,928 |
|
16,035 |
|
15,941 |
|
16,067 |
|
||||||||||||||||||||
Diluted Earnings Per Share | ||||||||||||||||||||||||||||
Net income |
$ |
|
3.08 |
|
$ |
|
3.27 |
|
$ |
|
5.79 |
|
$ |
|
5.93 |
|
||||||||||||
Average number of shares outstanding |
16,449 |
|
16,811 |
|
16,489 |
|
16,854 |
|
||||||||||||||||||||
(aa) |
Selling, general and administrative ("SG&A") expenses comprise (in thousands): | |||||||||||||||||||||||||||
Three Months Ended |
|
Six Months Ended |
||||||||||||||||||||||||||
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||||||||||||||||
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation plans |
$ |
|
70,300 |
|
$ |
|
66,296 |
|
$ |
|
140,504 |
|
$ |
|
132,517 |
|
||||||||||||
Long-term incentive compensation |
1,386 |
|
1,222 |
|
2,874 |
|
3,142 |
|
||||||||||||||||||||
Market value gains/(losses) related to deferred compensation trusts |
(130 |
) |
779 |
|
2,207 |
|
1,638 |
|
||||||||||||||||||||
Total SG&A expenses |
$ |
|
71,556 |
|
$ |
|
68,297 |
|
$ |
|
145,585 |
|
$ |
|
137,297 |
|
||||||||||||
(bb) |
Other income--net comprises (in thousands): | |||||||||||||||||||||||||||
Three Months Ended |
|
Six Months Ended |
||||||||||||||||||||||||||
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||||||||||||||||
Market value gains/(losses) related to deferred compensation trusts |
$ |
|
(130 |
) |
$ |
|
779 |
|
$ |
|
2,207 |
|
$ |
|
1,638 |
|
||||||||||||
Interest income |
112 |
|
259 |
|
214 |
|
417 |
|
||||||||||||||||||||
Other |
31 |
|
- |
|
31 |
|
1 |
|
||||||||||||||||||||
Total other income--net |
$ |
|
13 |
|
$ |
|
1,038 |
|
$ |
|
2,452 |
|
$ |
|
2,056 |
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||
CONSOLIDATED BALANCE SHEET | ||||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||||
|
||||||||||||||||||||
2019 |
|
2018 |
||||||||||||||||||
Assets | ||||||||||||||||||||
Current assets | ||||||||||||||||||||
Cash and cash equivalents |
$ |
|
3,323 |
|
$ |
|
12,668 |
|
||||||||||||
Accounts receivable less allowances |
136,113 |
|
119,206 |
|
||||||||||||||||
Inventories |
6,336 |
|
5,696 |
|
||||||||||||||||
Prepaid income taxes |
12,951 |
|
19,666 |
|
||||||||||||||||
Prepaid expenses |
21,455 |
|
16,205 |
|
||||||||||||||||
Total current assets |
180,178 |
|
173,441 |
|
||||||||||||||||
Investments of deferred compensation plans held in trust |
70,460 |
|
67,573 |
|
||||||||||||||||
Properties and equipment, at cost less accumulated depreciation |
149,917 |
|
145,903 |
|
||||||||||||||||
Assets held for sale |
15,750 |
- |
||||||||||||||||||
Lease right of use asset |
90,755 |
- |
||||||||||||||||||
Identifiable intangible assets less accumulated amortization |
67,511 |
|
55,250 |
|
||||||||||||||||
510,627 |
|
478,202 |
|
|||||||||||||||||
Other assets |
8,874 |
|
7,845 |
|
||||||||||||||||
Total Assets |
$ |
|
1,094,072 |
|
$ |
|
928,214 |
|
||||||||||||
Liabilities | ||||||||||||||||||||
Current liabilities | ||||||||||||||||||||
Accounts payable |
$ |
|
51,143 |
|
$ |
|
48,236 |
|
||||||||||||
Accrued insurance |
46,912 |
|
42,826 |
|
||||||||||||||||
Accrued compensation |
50,123 |
|
49,372 |
|
||||||||||||||||
Accrued legal |
8,431 |
|
823 |
|
||||||||||||||||
Short-term lease liability |
31,614 |
|
- |
|
||||||||||||||||
Other current liabilities |
35,446 |
|
25,159 |
|
||||||||||||||||
Total current liabilities |
223,669 |
|
166,416 |
|
||||||||||||||||
Deferred income taxes |
18,828 |
|
18,811 |
|
||||||||||||||||
Long-term debt |
85,000 |
|
103,400 |
|
||||||||||||||||
Deferred compensation liabilities |
70,273 |
|
66,154 |
|
||||||||||||||||
Long-term lease liability |
69,979 |
|
- |
|
||||||||||||||||
Other liabilities |
7,754 |
|
17,042 |
|
||||||||||||||||
Total Liabilities |
475,503 |
|
371,823 |
|
||||||||||||||||
Stockholders' Equity | ||||||||||||||||||||
Capital stock |
35,591 |
|
35,141 |
|
||||||||||||||||
Paid-in capital |
817,255 |
|
744,228 |
|
||||||||||||||||
Retained earnings |
1,311,446 |
|
1,129,289 |
|
||||||||||||||||
(1,548,138 |
) |
(1,354,538 |
) |
|||||||||||||||||
Deferred compensation payable in Company stock |
2,415 |
|
2,271 |
|
||||||||||||||||
Total Stockholders' Equity |
618,569 |
|
556,391 |
|
||||||||||||||||
Total Liabilities and Stockholders' Equity |
$ |
|
1,094,072 |
|
$ |
|
928,214 |
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||
CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||
Six Months Ended |
||||||||||||||||||||
2019 |
2018 |
|||||||||||||||||||
Cash Flows from Operating Activities | ||||||||||||||||||||
Net income |
$ |
|
95,396 |
|
$ |
|
99,967 |
|
||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||||||
Depreciation and amortization |
20,522 |
|
19,046 |
|
||||||||||||||||
Stock option expense |
8,018 |
|
7,305 |
|
||||||||||||||||
Litigation settlement |
6,000 |
|
- |
|
||||||||||||||||
(Benefit)/provision for deferred income taxes |
(2,769 |
) |
2,173 |
|
||||||||||||||||
Noncash long-term incentive compensation |
2,506 |
|
2,942 |
|
||||||||||||||||
Asset impairment loss |
2,266 |
|
- |
|
||||||||||||||||
Noncash directors' compensation |
767 |
|
766 |
|
||||||||||||||||
Amortization of debt issuance costs |
153 |
|
288 |
|
||||||||||||||||
Amortization of restricted stock awards |
- |
|
446 |
|
||||||||||||||||
Changes in operating assets and liabilities, excluding amounts acquired in business combinations: | ||||||||||||||||||||
Increase in accounts receivable |
(16,613 |
) |
(6,057 |
) |
||||||||||||||||
Increase in inventories |
(631 |
) |
(362 |
) |
||||||||||||||||
Increase in prepaid expenses |
(2,301 |
) |
(113 |
) |
||||||||||||||||
Decrease in accounts payable and other current liabilities |
(4,175 |
) |
(14,909 |
) |
||||||||||||||||
Change in current income taxes |
(2,249 |
) |
10,136 |
|
||||||||||||||||
Increase in other assets |
(4,653 |
) |
(5,667 |
) |
||||||||||||||||
Increase in other liabilities |
5,833 |
|
4,889 |
|
||||||||||||||||
Other sources |
837 |
|
186 |
|
||||||||||||||||
Net cash provided by operating activities |
108,907 |
|
121,036 |
|
||||||||||||||||
Cash Flows from Investing Activities | ||||||||||||||||||||
Capital expenditures |
(28,312 |
) |
(23,872 |
) |
||||||||||||||||
Business combinations, net of cash acquired |
- |
|
(1,875 |
) |
||||||||||||||||
Other (uses)/sources |
(137 |
) |
533 |
|
||||||||||||||||
Net cash used by investing activities |
(28,449 |
) |
(25,214 |
) |
||||||||||||||||
Cash Flows from Financing Activities | ||||||||||||||||||||
Payments on revolving line of credit |
(227,000 |
) |
(281,150 |
) |
||||||||||||||||
Proceeds from revolving line of credit |
222,800 |
|
358,350 |
|
||||||||||||||||
Purchases of treasury stock |
(71,926 |
) |
(84,304 |
) |
||||||||||||||||
Proceeds from exercise of stock options |
16,517 |
|
20,209 |
|
||||||||||||||||
Capital stock surrendered to pay taxes on stock-based compensation |
(14,884 |
) |
(21,022 |
) |
||||||||||||||||
Dividends paid |
(9,567 |
) |
(9,016 |
) |
||||||||||||||||
Change in cash overdrafts payable |
1,710 |
|
(711 |
) |
||||||||||||||||
Payments on other long-term debt |
- |
|
(75,000 |
) |
||||||||||||||||
Debt issuance costs |
- |
|
(968 |
) |
||||||||||||||||
Other sources/(uses) |
384 |
|
(663 |
) |
||||||||||||||||
Net cash used by financing activities |
(81,966 |
) |
(94,275 |
) |
||||||||||||||||
(Decrease)/increase in Cash and Cash Equivalents |
(1,508 |
) |
1,547 |
|
||||||||||||||||
Cash and cash equivalents at beginning of year |
4,831 |
|
11,121 |
|
||||||||||||||||
Cash and cash equivalents at end of year |
$ |
|
3,323 |
|
$ |
|
12,668 |
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | ||||||||||||||||||||||||
FOR THE THREE MONTHS ENDED |
||||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||||
|
|
|
|
|
|
Chemed |
||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
||||||||||||||||||
2019 |
||||||||||||||||||||||||
Service revenues and sales (a) |
$ |
|
312,750 |
|
$ |
|
160,834 |
|
$ |
|
- |
|
$ |
|
473,584 |
|
||||||||
Cost of services provided and goods sold |
241,104 |
|
82,533 |
|
- |
|
323,637 |
|
||||||||||||||||
Selling, general and administrative expenses (a) |
21,682 |
|
39,377 |
|
10,497 |
|
71,556 |
|
||||||||||||||||
Depreciation |
4,831 |
|
5,017 |
|
39 |
|
9,887 |
|
||||||||||||||||
Amortization |
18 |
|
388 |
|
- |
|
406 |
|
||||||||||||||||
Other operating expense (a) |
69 |
|
235 |
|
2,266 |
|
2,570 |
|
||||||||||||||||
Total costs and expenses |
267,704 |
|
127,550 |
|
12,802 |
|
408,056 |
|
||||||||||||||||
Income/(loss) from operations |
45,046 |
|
33,284 |
|
(12,802 |
) |
65,528 |
|
||||||||||||||||
Interest expense |
(53 |
) |
(100 |
) |
(1,084 |
) |
(1,237 |
) |
||||||||||||||||
Intercompany interest income/(expense) |
4,382 |
|
2,180 |
|
(6,562 |
) |
- |
|
||||||||||||||||
Other income/(expense)—net |
101 |
|
42 |
|
(130 |
) |
13 |
|
||||||||||||||||
Income/(loss) before income taxes |
49,476 |
|
35,406 |
|
(20,578 |
) |
64,304 |
|
||||||||||||||||
Income taxes (a) |
(12,137 |
) |
(8,231 |
) |
6,793 |
|
(13,575 |
) |
||||||||||||||||
Net income/(loss) |
$ |
|
37,339 |
|
$ |
|
27,175 |
|
$ |
|
(13,785 |
) |
$ |
|
50,729 |
|
||||||||
2018 |
||||||||||||||||||||||||
Service revenues and sales (b) |
$ |
|
296,799 |
|
$ |
|
145,014 |
|
$ |
|
- |
|
$ |
|
441,813 |
|
||||||||
Cost of services provided and goods sold |
233,073 |
|
72,668 |
|
- |
|
305,741 |
|
||||||||||||||||
Selling, general and administrative expenses (b) |
20,702 |
|
35,909 |
|
11,686 |
|
68,297 |
|
||||||||||||||||
Depreciation |
5,050 |
|
4,628 |
|
40 |
|
9,718 |
|
||||||||||||||||
Amortization |
- |
|
34 |
|
- |
|
34 |
|
||||||||||||||||
Other operating income (b) |
(67 |
) |
(51 |
) |
- |
|
(118 |
) |
||||||||||||||||
Total costs and expenses |
258,758 |
|
113,188 |
|
11,726 |
|
383,672 |
|
||||||||||||||||
Income/(loss) from operations |
38,041 |
|
31,826 |
|
(11,726 |
) |
58,141 |
|
||||||||||||||||
Interest expense |
(53 |
) |
(92 |
) |
(1,379 |
) |
(1,524 |
) |
||||||||||||||||
Intercompany interest income/(expense) |
3,124 |
|
1,739 |
|
(4,863 |
) |
- |
|
||||||||||||||||
Other income—net |
238 |
|
21 |
|
779 |
|
1,038 |
|
||||||||||||||||
Income/(loss) before income taxes |
41,350 |
|
33,494 |
|
(17,189 |
) |
57,655 |
|
||||||||||||||||
Income taxes (b) |
(9,565 |
) |
(8,196 |
) |
15,077 |
|
(2,684 |
) |
||||||||||||||||
Net income/(loss) |
$ |
|
31,785 |
|
$ |
|
25,298 |
|
$ |
|
(2,112 |
) |
$ |
|
54,971 |
|
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | ||||||||||||||||||||||||
FOR THE SIX MONTHS ENDED |
||||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||||
|
|
|
|
|
|
Chemed |
||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
||||||||||||||||||
2019 |
||||||||||||||||||||||||
Service revenues and sales (a) |
$ |
|
619,531 |
|
$ |
|
316,087 |
|
$ |
|
- |
|
$ |
|
935,618 |
|
||||||||
Cost of services provided and goods sold |
480,847 |
|
164,741 |
|
- |
|
645,588 |
|
||||||||||||||||
Selling, general and administrative expenses (a) |
43,218 |
|
78,978 |
|
23,389 |
|
145,585 |
|
||||||||||||||||
Depreciation |
9,539 |
|
9,980 |
|
78 |
|
19,597 |
|
||||||||||||||||
Amortization |
35 |
|
890 |
|
- |
|
925 |
|
||||||||||||||||
Other operating expense (a) |
6,423 |
|
234 |
|
2,266 |
|
8,923 |
|
||||||||||||||||
Total costs and expenses |
540,062 |
|
254,823 |
|
25,733 |
|
820,618 |
|
||||||||||||||||
Income/(loss) from operations |
79,469 |
|
61,264 |
|
(25,733 |
) |
115,000 |
|
||||||||||||||||
Interest expense |
(101 |
) |
(194 |
) |
(2,066 |
) |
(2,361 |
) |
||||||||||||||||
Intercompany interest income/(expense) |
8,777 |
|
4,375 |
|
(13,152 |
) |
- |
|
||||||||||||||||
Other income—net |
188 |
|
56 |
|
2,208 |
|
2,452 |
|
||||||||||||||||
Income/(loss) before income taxes |
88,333 |
|
65,501 |
|
(38,743 |
) |
115,091 |
|
||||||||||||||||
Income taxes (a) |
(21,707 |
) |
(15,339 |
) |
17,351 |
|
(19,695 |
) |
||||||||||||||||
Net income/(loss) |
$ |
|
66,626 |
|
$ |
|
50,162 |
|
$ |
|
(21,392 |
) |
$ |
|
95,396 |
|
||||||||
2018 |
||||||||||||||||||||||||
Service revenues and sales (b) |
$ |
|
588,813 |
|
$ |
|
292,176 |
|
$ |
|
- |
|
$ |
|
880,989 |
|
||||||||
Cost of services provided and goods sold |
460,329 |
|
149,948 |
|
- |
|
610,277 |
|
||||||||||||||||
Selling, general and administrative expenses (b) |
41,213 |
|
72,006 |
|
24,078 |
|
137,297 |
|
||||||||||||||||
Depreciation |
9,846 |
|
9,072 |
|
67 |
|
18,985 |
|
||||||||||||||||
Amortization |
- |
|
61 |
|
- |
|
61 |
|
||||||||||||||||
Other operating expense (b) |
(84 |
) |
(85 |
) |
- |
|
(169 |
) |
||||||||||||||||
Total costs and expenses |
511,304 |
|
231,002 |
|
24,145 |
|
766,451 |
|
||||||||||||||||
Income/(loss) from operations |
77,509 |
|
61,174 |
|
(24,145 |
) |
114,538 |
|
||||||||||||||||
Interest expense |
(104 |
) |
(184 |
) |
(2,443 |
) |
(2,731 |
) |
||||||||||||||||
Intercompany interest income/(expense) |
6,218 |
|
3,417 |
|
(9,635 |
) |
- |
|
||||||||||||||||
Other income—net |
380 |
|
37 |
|
1,639 |
|
2,056 |
|
||||||||||||||||
Income/(loss) before income taxes |
84,003 |
|
64,444 |
|
(34,584 |
) |
113,863 |
|
||||||||||||||||
Income taxes (b) |
(20,203 |
) |
(16,208 |
) |
22,515 |
|
(13,896 |
) |
||||||||||||||||
Net income/(loss) |
$ |
|
63,800 |
|
$ |
|
48,236 |
|
$ |
|
(12,069 |
) |
$ |
|
99,967 |
|
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | ||||||||||||||||||||||||||
FOR THE THREE MONTHS ENDED |
||||||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||||||
|
|
|
|
|
|
Chemed |
||||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
||||||||||||||||||||
2019 |
||||||||||||||||||||||||||
Net income/(loss) |
$ |
|
37,339 |
|
$ |
|
27,175 |
|
$ |
|
(13,785 |
) |
$ |
|
50,729 |
|
||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Interest expense |
53 |
|
100 |
|
1,084 |
|
1,237 |
|
||||||||||||||||||
Income taxes |
12,137 |
|
8,231 |
|
(6,793 |
) |
13,575 |
|
||||||||||||||||||
Depreciation |
4,831 |
|
5,017 |
|
39 |
|
9,887 |
|
||||||||||||||||||
Amortization |
18 |
|
388 |
|
- |
|
406 |
|
||||||||||||||||||
EBITDA |
54,378 |
|
40,911 |
|
(19,455 |
) |
75,834 |
|
||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Intercompany interest expense/(income) |
(4,382 |
) |
(2,180 |
) |
6,562 |
|
- |
|
||||||||||||||||||
Interest income |
(69 |
) |
(43 |
) |
- |
|
(112 |
) |
||||||||||||||||||
Stock option expense |
- |
|
- |
|
3,929 |
|
3,929 |
|
||||||||||||||||||
Impairment loss on transportation equipment |
- |
|
- |
|
2,266 |
|
2,266 |
|
||||||||||||||||||
Medicare cap sequestration adjustment |
1,689 |
|
- |
|
- |
|
1,689 |
|
||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
1,386 |
|
1,386 |
|
||||||||||||||||||
Acquisition expense |
- |
|
97 |
|
- |
|
97 |
|
||||||||||||||||||
Adjusted EBITDA |
$ |
|
51,616 |
|
$ |
|
38,785 |
|
$ |
|
(5,312 |
) |
$ |
|
85,089 |
|
||||||||||
2018 |
||||||||||||||||||||||||||
Net income/(loss) |
$ |
|
31,785 |
|
$ |
|
25,298 |
|
$ |
|
(2,112 |
) |
$ |
|
54,971 |
|
||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Interest expense |
53 |
|
92 |
|
1,379 |
|
1,524 |
|
||||||||||||||||||
Income taxes |
9,565 |
|
8,196 |
|
(15,077 |
) |
2,684 |
|
||||||||||||||||||
Depreciation |
5,050 |
|
4,628 |
|
40 |
|
9,718 |
|
||||||||||||||||||
Amortization |
- |
|
34 |
|
- |
|
34 |
|
||||||||||||||||||
EBITDA |
46,453 |
|
38,248 |
|
(15,770 |
) |
68,931 |
|
||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Intercompany interest expense/(income) |
(3,124 |
) |
(1,739 |
) |
4,863 |
|
- |
|
||||||||||||||||||
Interest income |
(237 |
) |
(22 |
) |
- |
|
(259 |
) |
||||||||||||||||||
Stock option expense |
- |
|
- |
|
3,652 |
|
3,652 |
|
||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
1,222 |
|
1,222 |
|
||||||||||||||||||
Litigation settlement |
(204 |
) |
- |
|
- |
|
(204 |
) |
||||||||||||||||||
Medicare cap sequestration adjustment |
185 |
|
- |
|
- |
|
185 |
|
||||||||||||||||||
Amortization of stock awards |
37 |
|
35 |
|
83 |
|
155 |
|
||||||||||||||||||
Adjusted EBITDA |
$ |
|
43,110 |
|
$ |
|
36,522 |
|
$ |
|
(5,950 |
) |
$ |
|
73,682 |
|
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | ||||||||||||||||||||||||||
FOR THE SIX MONTHS ENDED 30, 2019 AND 2018 | ||||||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||||||
|
|
|
|
|
|
Chemed |
||||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
||||||||||||||||||||
2019 |
||||||||||||||||||||||||||
Net income/(loss) |
$ |
|
66,626 |
|
$ |
|
50,162 |
|
$ |
|
(21,392 |
) |
$ |
|
95,396 |
|
||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Interest expense |
101 |
|
194 |
|
2,066 |
|
2,361 |
|
||||||||||||||||||
Income taxes |
21,707 |
|
15,339 |
|
(17,351 |
) |
19,695 |
|
||||||||||||||||||
Depreciation |
9,539 |
|
9,980 |
|
78 |
|
19,597 |
|
||||||||||||||||||
Amortization |
35 |
|
890 |
|
- |
|
925 |
|
||||||||||||||||||
EBITDA |
98,008 |
|
76,565 |
|
(36,599 |
) |
137,974 |
|
||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Intercompany interest expense/(income) |
(8,777 |
) |
(4,375 |
) |
13,152 |
|
- |
|
||||||||||||||||||
Interest income |
(157 |
) |
(56 |
) |
- |
|
(213 |
) |
||||||||||||||||||
Stock option expense |
- |
|
- |
|
8,018 |
|
8,018 |
|
||||||||||||||||||
Litigation settlement |
6,000 |
|
- |
|
- |
|
6,000 |
|
||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
2,874 |
|
2,874 |
|
||||||||||||||||||
Impairment loss on transportation equipment |
- |
|
- |
|
2,266 |
|
2,266 |
|
||||||||||||||||||
Medicare cap sequestration adjustment |
2,204 |
|
- |
|
- |
|
2,204 |
|
||||||||||||||||||
Non cash ASC 842 expenses/(benefit) |
656 |
|
55 |
|
(163 |
) |
548 |
|
||||||||||||||||||
Acquisition Expense |
- |
|
97 |
|
120 |
|
217 |
|
||||||||||||||||||
Adjusted EBITDA |
$ |
|
97,934 |
|
$ |
|
72,286 |
|
$ |
|
(10,332 |
) |
$ |
|
159,888 |
|
||||||||||
2018 |
||||||||||||||||||||||||||
Net income/(loss) |
$ |
|
63,800 |
|
$ |
|
48,236 |
|
$ |
|
(12,069 |
) |
$ |
|
99,967 |
|
||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Interest expense |
104 |
|
184 |
|
2,443 |
|
2,731 |
|
||||||||||||||||||
Income taxes |
20,203 |
|
16,208 |
|
(22,515 |
) |
13,896 |
|
||||||||||||||||||
Depreciation |
9,846 |
|
9,072 |
|
67 |
|
18,985 |
|
||||||||||||||||||
Amortization |
- |
|
61 |
|
- |
|
61 |
|
||||||||||||||||||
EBITDA |
93,953 |
|
73,761 |
|
(32,074 |
) |
135,640 |
|
||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||||
Intercompany interest expense/(income) |
(6,218 |
) |
(3,417 |
) |
9,635 |
|
- |
|
||||||||||||||||||
Interest income |
(380 |
) |
(37 |
) |
- |
|
(417 |
) |
||||||||||||||||||
Stock option expense |
- |
|
- |
|
7,305 |
|
7,305 |
|
||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
3,142 |
|
3,142 |
|
||||||||||||||||||
Medicare cap sequestration adjustment |
537 |
|
- |
|
- |
|
537 |
|
||||||||||||||||||
Amortization of stock awards |
107 |
|
100 |
|
239 |
|
446 |
|
||||||||||||||||||
Litigation settlement |
(204 |
) |
- |
|
- |
|
(204 |
) |
||||||||||||||||||
Adjusted EBITDA |
$ |
|
87,795 |
|
$ |
|
70,407 |
|
$ |
|
(11,753 |
) |
$ |
|
146,449 |
|
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||||
RECONCILIATION OF ADJUSTED NET INCOME | ||||||||||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||||||||||
Three Months Ended |
|
Six Months Ended |
||||||||||||||||||||||||
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||||||||||||||
Net income as reported |
$ |
|
50,729 |
|
$ |
|
54,971 |
|
$ |
|
95,396 |
|
$ |
|
99,967 |
|
||||||||||
Add/(deduct) pre-tax cost of: | ||||||||||||||||||||||||||
Stock option expense |
3,929 |
|
3,652 |
|
8,018 |
|
7,305 |
|
||||||||||||||||||
Litigation settlement |
- |
|
(204 |
) |
6,000 |
|
(204 |
) |
||||||||||||||||||
Long-term incentive compensation |
1,386 |
|
1,222 |
|
2,874 |
|
3,142 |
|
||||||||||||||||||
Impairment loss on transportation equipment |
2,266 |
|
- |
|
2,266 |
|
- |
|
||||||||||||||||||
Medicare cap sequestration adjustments |
1,689 |
|
185 |
|
2,204 |
|
537 |
|
||||||||||||||||||
Amortization of acquired and cancelled franchise agreements |
331 |
|
- |
|
772 |
|
- |
|
||||||||||||||||||
Non cash ASC 842 expenses |
- |
|
- |
|
548 |
|
- |
|
||||||||||||||||||
Acquisition expenses |
97 |
|
- |
|
217 |
|
- |
|
||||||||||||||||||
Add/(deduct) tax impacts: | ||||||||||||||||||||||||||
Tax impact of the above pre-tax adjustments (1) |
(2,000 |
) |
(966 |
) |
(4,961 |
) |
(2,238 |
) |
||||||||||||||||||
Excess tax benefits on stock compensation |
(3,212 |
) |
(11,702 |
) |
(9,944 |
) |
(15,500 |
) |
||||||||||||||||||
Adjusted net income |
$ |
|
55,215 |
|
$ |
|
47,158 |
|
$ |
|
103,390 |
|
$ |
|
93,009 |
|
||||||||||
Diluted Earnings Per Share As Reported | ||||||||||||||||||||||||||
Net income |
$ |
|
3.08 |
|
$ |
|
3.27 |
|
$ |
|
5.79 |
|
$ |
|
5.93 |
|
||||||||||
Average number of shares outstanding |
16,449 |
|
16,811 |
|
16,489 |
|
16,854 |
|
||||||||||||||||||
Adjusted Diluted Earnings Per Share | ||||||||||||||||||||||||||
Adjusted net income |
$ |
|
3.36 |
|
$ |
|
2.81 |
|
$ |
|
6.27 |
|
$ |
|
5.52 |
|
||||||||||
Average number of shares outstanding |
16,449 |
|
16,811 |
|
16,489 |
|
16,854 |
|
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. | ||||||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||
OPERATING STATISTICS FOR VITAS SEGMENT | |||||||||||||||||||||
(unaudited) | |||||||||||||||||||||
Three Months Ended |
|
Six Months Ended |
|||||||||||||||||||
OPERATING STATISTICS |
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||||||||
Net revenue ( |
|||||||||||||||||||||
Homecare |
$ |
266,461 |
$ |
250,381 |
$ |
525,312 |
$ |
491,412 |
|||||||||||||
Inpatient |
22,894 |
20,077 |
45,464 |
42,186 |
|||||||||||||||||
Continuous care |
30,786 |
30,513 |
63,030 |
61,279 |
|||||||||||||||||
Other |
2,237 |
1,998 |
4,242 |
3,740 |
|||||||||||||||||
Subtotal |
$ |
322,378 |
$ |
302,969 |
$ |
638,048 |
$ |
598,617 |
|||||||||||||
Room and board, net |
(2,710 |
) |
(2,675 |
) |
(5,252 |
) |
(5,294 |
) |
|||||||||||||
Contractual allowances |
(3,720 |
) |
(2,959 |
) |
(6,667 |
) |
(5,792 |
) |
|||||||||||||
Medicare cap allowance |
(3,198 |
) |
(536 |
) |
(6,598 |
) |
1,282 |
||||||||||||||
Net Revenue |
$ |
312,750 |
$ |
296,799 |
$ |
619,531 |
$ |
588,813 |
|||||||||||||
Net revenue as a percent of total before Medicare cap allowance | |||||||||||||||||||||
Homecare |
82.7 |
% |
82.6 |
% |
82.3 |
% |
82.1 |
% |
|||||||||||||
Inpatient |
7.1 |
6.6 |
7.1 |
7.0 |
|||||||||||||||||
Continuous care |
9.5 |
10.1 |
9.9 |
10.2 |
|||||||||||||||||
Other |
0.7 |
0.7 |
0.7 |
0.7 |
|||||||||||||||||
Subtotal |
100.0 |
100.0 |
100.0 |
100.0 |
|||||||||||||||||
Room and board, net |
(0.8 |
) |
(0.9 |
) |
(0.8 |
) |
(0.9 |
) |
|||||||||||||
Contractual allowances |
(1.2 |
) |
(1.0 |
) |
(1.0 |
) |
(1.0 |
) |
|||||||||||||
Medicare cap allowance |
(1.0 |
) |
(0.1 |
) |
(1.0 |
) |
0.3 |
||||||||||||||
Net Revenue |
97.0 |
% |
98.0 |
% |
97.2 |
% |
98.4 |
% |
|||||||||||||
Average daily census ("ADC") (days) | |||||||||||||||||||||
Homecare |
14,482 |
13,583 |
14,364 |
13,375 |
|||||||||||||||||
Nursing home |
3,382 |
3,275 |
3,318 |
3,245 |
|||||||||||||||||
Routine homecare |
17,864 |
16,858 |
17,682 |
16,620 |
|||||||||||||||||
Inpatient |
358 |
318 |
359 |
335 |
|||||||||||||||||
Continuous care |
459 |
467 |
474 |
473 |
|||||||||||||||||
Total |
18,681 |
17,643 |
18,515 |
17,428 |
|||||||||||||||||
Total Admissions |
17,491 |
16,858 |
35,249 |
35,137 |
|||||||||||||||||
Total Discharges |
17,008 |
16,474 |
34,350 |
34,054 |
|||||||||||||||||
Average length of stay (days) |
91.1 |
89.0 |
91.2 |
88.4 |
|||||||||||||||||
Median length of stay (days) |
16.0 |
17.0 |
15.0 |
16.0 |
|||||||||||||||||
ADC by major diagnosis | |||||||||||||||||||||
Cerebro |
35.7 |
% |
36.2 |
% |
35.8 |
% |
36.4 |
% |
|||||||||||||
Neurological |
20.4 |
18.6 |
20.2 |
18.6 |
|||||||||||||||||
Cancer |
12.7 |
13.9 |
12.7 |
13.9 |
|||||||||||||||||
Cardio |
17.0 |
16.6 |
16.9 |
16.4 |
|||||||||||||||||
Respiratory |
8.2 |
8.3 |
8.2 |
8.2 |
|||||||||||||||||
Other |
6.0 |
6.4 |
6.2 |
6.5 |
|||||||||||||||||
Total |
100.0 |
% |
100.0 |
% |
100.0 |
% |
100.0 |
% |
|||||||||||||
Admissions by major diagnosis | |||||||||||||||||||||
Cerebro |
20.6 |
% |
21.7 |
% |
20.7 |
% |
22.2 |
% |
|||||||||||||
Neurological |
12.2 |
11.1 |
12.5 |
11.2 |
|||||||||||||||||
Cancer |
29.2 |
30.5 |
28.6 |
29.2 |
|||||||||||||||||
Cardio |
16.0 |
15.6 |
16.1 |
15.6 |
|||||||||||||||||
Respiratory |
11.7 |
10.8 |
11.8 |
11.3 |
|||||||||||||||||
Other |
10.3 |
10.3 |
10.3 |
10.5 |
|||||||||||||||||
Total |
100.0 |
% |
100.0 |
% |
100.0 |
% |
100.0 |
% |
|||||||||||||
Estimated uncollectible accounts as a percent of revenues |
1.2 |
% |
|
|
1.0 |
% |
|
|
1.1 |
% |
|
|
1.0 |
% |
|||||||
Accounts receivable -- |
|
|
|
|
|
|
|
|
|
|
|||||||||||
Days of revenue outstanding- excluding unapplied Medicare payments |
32.7 |
|
|
|
31.9 |
|
|
|
n.a. |
|
|
n.a. |
|||||||||
Days of revenue outstanding- including unapplied Medicare payments |
27.7 |
|
|
|
25.6 |
|
|
|
n.a. |
|
|
n.a. |
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||||||
FOOTNOTES TO FINANCIAL STATEMENTS | |||||||||||||||||||||||||||
FOR THE THREE AND SIX MONTHS ENDED |
|||||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||||
(a) |
Included in the results of operations for 2019 are the following significant credits/(charges) which may not be indicative of ongoing operations | ||||||||||||||||||||||||||
(in thousands): | |||||||||||||||||||||||||||
Three Months Ended |
|||||||||||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
|||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||||
Medicare cap sequestration adjustment |
$ |
|
(1,689 |
) |
$ |
|
- |
|
$ |
|
- |
|
$ |
|
(1,689 |
) |
|||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||||
Stock option expense |
- |
|
- |
|
(3,929 |
) |
(3,929 |
) |
|||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
(1,386 |
) |
(1,386 |
) |
|||||||||||||||||||
Amortization of acquired and cancelled franchise agreements |
- |
|
(331 |
) |
- |
|
(331 |
) |
|||||||||||||||||||
Acquisition expense |
- |
|
(97 |
) |
- |
|
(97 |
) |
|||||||||||||||||||
Other operating expenses: | |||||||||||||||||||||||||||
Impairment loss on transportation equipment |
- |
|
- |
|
(2,266 |
) |
(2,266 |
) |
|||||||||||||||||||
Pretax impact on earnings |
(1,689 |
) |
(428 |
) |
(7,581 |
) |
(9,698 |
) |
|||||||||||||||||||
Excess tax benefits on stock compensation |
- |
|
- |
|
3,212 |
|
3,212 |
|
|||||||||||||||||||
Income tax benefit on the above |
435 |
|
113 |
|
1,452 |
|
2,000 |
|
|||||||||||||||||||
After-tax impact on earnings |
$ |
|
(1,254 |
) |
$ |
|
(315 |
) |
$ |
|
(2,917 |
) |
$ |
|
(4,486 |
) |
|||||||||||
Six Months Ended |
|||||||||||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
|||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||||
Medicare cap sequestration adjustment |
$ |
|
(2,204 |
) |
$ |
|
- |
|
$ |
|
- |
|
$ |
|
(2,204 |
) |
|||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||||
Stock option expense |
- |
|
- |
|
(8,018 |
) |
(8,018 |
) |
|||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
(2,874 |
) |
(2,874 |
) |
|||||||||||||||||||
Amortization of acquired and cancelled franchise agreements |
- |
|
(772 |
) |
- |
|
(772 |
) |
|||||||||||||||||||
Non cash ASC 842 (expenses)/benefit |
(656 |
) |
(55 |
) |
163 |
|
(548 |
) |
|||||||||||||||||||
Acquisition expense |
- |
|
(97 |
) |
(120 |
) |
(217 |
) |
|||||||||||||||||||
Other operating expenses: | |||||||||||||||||||||||||||
Litigation settlement |
(6,000 |
) |
- |
|
- |
|
(6,000 |
) |
|||||||||||||||||||
Impairment loss on transportation equipment |
- |
|
- |
|
(2,266 |
) |
(2,266 |
) |
|||||||||||||||||||
Pretax impact on earnings |
(8,860 |
) |
(924 |
) |
(13,115 |
) |
(22,899 |
) |
|||||||||||||||||||
Excess tax benefits on stock compensation |
- |
|
- |
|
9,944 |
|
9,944 |
|
|||||||||||||||||||
Income tax benefit on the above |
2,254 |
|
245 |
|
2,462 |
|
4,961 |
|
|||||||||||||||||||
After-tax impact on earnings |
$ |
|
(6,606 |
) |
$ |
|
(679 |
) |
$ |
|
(709 |
) |
$ |
|
(7,994 |
) |
|||||||||||
(b) |
Included in the results of operations for 2018 are the following significant credits/(charges) which may not be indicative of ongoing operations | ||||||||||||||||||||||||||
(in thousands): | |||||||||||||||||||||||||||
Three Months Ended |
|||||||||||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
|||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||||
Medicare cap sequestration adjustment |
$ |
|
(185 |
) |
$ |
|
- |
|
$ |
|
- |
|
$ |
|
(185 |
) |
|||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||||
Stock option expense |
- |
|
- |
|
(3,652 |
) |
(3,652 |
) |
|||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
(1,222 |
) |
(1,222 |
) |
|||||||||||||||||||
Other operating expenses: | |||||||||||||||||||||||||||
Litigation settlements |
204 |
|
- |
|
- |
|
204 |
|
|||||||||||||||||||
Pretax impact on earnings |
19 |
|
- |
|
(4,874 |
) |
(4,855 |
) |
|||||||||||||||||||
Excess tax benefits on stock compensation |
- |
|
- |
|
11,702 |
|
11,702 |
|
|||||||||||||||||||
Income tax benefit on the above |
(5 |
) |
- |
|
971 |
|
966 |
|
|||||||||||||||||||
After-tax impact on earnings |
$ |
|
14 |
|
$ |
|
- |
|
$ |
|
7,799 |
|
$ |
|
7,813 |
|
|||||||||||
Six Months Ended |
|||||||||||||||||||||||||||
VITAS |
|
|
|
Corporate |
|
Consolidated |
|||||||||||||||||||||
Service revenues and sales: | |||||||||||||||||||||||||||
Medicare cap sequestration adjustment |
$ |
|
(537 |
) |
$ |
|
- |
|
$ |
|
- |
|
$ |
|
(537 |
) |
|||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||||
Stock option expense |
- |
|
- |
|
(7,305 |
) |
(7,305 |
) |
|||||||||||||||||||
Long-term incentive compensation |
- |
|
- |
|
(3,142 |
) |
(3,142 |
) |
|||||||||||||||||||
Other operating expenses: | |||||||||||||||||||||||||||
Litigation settlement |
204 |
|
- |
|
- |
|
204 |
|
|||||||||||||||||||
Pretax impact on earnings |
(333 |
) |
- |
|
(10,447 |
) |
(10,780 |
) |
|||||||||||||||||||
Excess tax benefits on stock compensation |
- |
|
- |
|
15,500 |
|
15,500 |
|
|||||||||||||||||||
Income tax benefit on the above |
84 |
|
- |
|
2,154 |
|
2,238 |
|
|||||||||||||||||||
After-tax impact on earnings |
$ |
|
(249 |
) |
$ |
|
- |
|
$ |
|
7,207 |
|
$ |
|
6,958 |
|
(c) |
VITAS has 11 large (greater than 450 ADC), 19 medium (greater than 200 but less than 450 ADC) and 18 small (less than 200 ADC) hospice programs. Of VITAS' 30 Medicare provider numbers, 25 provider numbers have a Medicare cap cushion of 5% or greater during the current cap year, one provider number has a cap cushion between 0% and 5%, and four provider numbers have a Medicare cap liability. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190725005666/en/
Source:
RGA Elects New Member to Board of Directors
AM Best Revises Outlooks to Stable for BCBSM, Inc., HMO Minnesota and MII Life Insurance, Incorporated
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News